Androgen Receptor and SRY/SOX Interaction in Prostate

前列腺中雄激素受体和 SRY/SOX 相互作用

基本信息

  • 批准号:
    6671899
  • 负责人:
  • 金额:
    $ 12.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-30 至 2008-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Androgen receptor (AR) plays an important role in the development and growth, as well as pathogenesis of prostate. Our recent results indicate that AR activity can be modulated by SRY, the male sex-determining factor. The AR/SRY directly interact with each other via their respective DNA binding domains. The SRY DNA binding domain, the HMG, is highly conserved among its family members, namely the SOX proteins. In deed, the AR DBD can interact with a variety of SOX proteins. AR was also able to suppress SRY/SOX9 transciptional activation. Moreover, SRY can interact with other steroid hormone receptors, such as estrogen and glucocoticoid receptors, but not with the related nuclear receptor, thyroid receptor. These results suggest that there is a general and specific protein interaction between the SRY/SOX and steroid hormone receptor family proteins. SRY protein has been detected in the prostate tissue, cDNA microarray analysis has reveals the presence of several SOX proteins in the normal prostate and prostate cancers. This proposal is define the biological significance of the interaction of AR and SRY/SOX families, which are both proven to be crucial for cell and tissue growth and differentiation. Studies are designed to address the mechanism of AR and SRY/SOX protein interaction. Aim 1. is to will determine the molecular details of AR-SRY interaction domains by mutational analysis. Aim 2. is to define the potential mechanism of AR-SRY mutual inhibition and test the hypothesis whether the inhibition mediated through interference of DNA binding; through recruitment of corepressor(s); or by interference of coactivator binding to AR or of AR N- and C-terminal interaction. Aim 3 it to assess the temporal and cell specific SRY/SOX protein expression in normal and abnormal prostate, which will shed light to their potential role in modulating AR functions. These studies will provide new understandings to the biological mechanisms of normal prostate development, to the pathogenesis of prostate hyperplasia and cancer. SRY mediated AR interference may also provide a tool for the design of more efficiently and specifically AR antagonist. My carrier goal is to become an independent physician scientist and doing research, which will lead to better understanding of human health and disease. This grant will allow me protected time to further expand my knowledge on uroglocal pathology, sharpen grant writing skills and general new data that will lead to future success in RO1 application.
描述(由申请人提供): 雄激素受体(Androgen receptor,AR)在前列腺的生长发育及发病机制中起重要作用。我们最近的研究结果表明,AR活动可以调制SRY,男性性别决定因子。AR/SRY通过它们各自的DNA结合结构域直接相互作用。SRY DNA结合结构域HMG在其家族成员即SOX蛋白中高度保守。事实上,AR DBD可以与多种SOX蛋白相互作用。AR还能够抑制SRY/SOX 9转录激活。此外,SRY还能与其它类固醇激素受体如雌激素受体、糖皮质激素受体等相互作用,但不与相关的核受体甲状腺受体相互作用。这些结果表明SRY/SOX和类固醇激素受体家族蛋白之间存在普遍和特异的蛋白质相互作用。SRY蛋白在前列腺组织中已被检测到,cDNA微阵列分析显示,在正常前列腺和前列腺癌中存在多种SOX蛋白。本研究旨在阐明AR和SRY/SOX家族相互作用的生物学意义,这两个家族都被证明对细胞和组织的生长和分化至关重要。研究旨在解决AR和SRY/SOX蛋白相互作用的机制。 目标1。将通过突变分析确定AR-SRY相互作用结构域的分子细节。目标二。确定AR-SRY相互抑制的潜在机制,并检验抑制是否通过干扰DNA结合、通过募集辅阻遏物、或通过干扰辅激活物与AR结合或AR N-和C-末端相互作用介导。目的3研究SRY/SOX蛋白在正常和异常前列腺组织中的时间和细胞特异性表达,探讨其在调节AR功能中的作用。 这些研究将为前列腺正常发育的生物学机制、前列腺增生和癌症的发病机制提供新的认识。SRY介导的AR干扰也可能为设计更有效、更特异的AR拮抗剂提供工具。 我的目标是成为一名独立的医生科学家和做研究,这将导致更好地了解人类健康和疾病。这笔赠款将使我有受保护的时间,以进一步扩大我对uroglocal病理学的知识,提高赠款写作技巧和一般的新数据,这将导致未来的成功RO 1应用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xin Yuan其他文献

Xin Yuan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xin Yuan', 18)}}的其他基金

SOX9 in prostate cancer development and progression
SOX9 在前列腺癌发生和进展中的作用
  • 批准号:
    8233930
  • 财政年份:
    2008
  • 资助金额:
    $ 12.9万
  • 项目类别:
SOX9 in prostate cancer development and progression
SOX9 在前列腺癌发生和进展中的作用
  • 批准号:
    7791349
  • 财政年份:
    2008
  • 资助金额:
    $ 12.9万
  • 项目类别:
SOX9 in prostate cancer development and progression
SOX9 在前列腺癌发生和进展中的作用
  • 批准号:
    7588874
  • 财政年份:
    2008
  • 资助金额:
    $ 12.9万
  • 项目类别:
SOX9 in prostate cancer development and progression
SOX9 在前列腺癌发生和进展中的作用
  • 批准号:
    8039096
  • 财政年份:
    2008
  • 资助金额:
    $ 12.9万
  • 项目类别:
Androgen Receptor and SRY/SOX Interaction in Prostate
前列腺中雄激素受体和 SRY/SOX 相互作用
  • 批准号:
    6895152
  • 财政年份:
    2003
  • 资助金额:
    $ 12.9万
  • 项目类别:
Androgen Receptor and SRY/SOX Interaction in Prostate
前列腺中雄激素受体和 SRY/SOX 相互作用
  • 批准号:
    6802344
  • 财政年份:
    2003
  • 资助金额:
    $ 12.9万
  • 项目类别:
Androgen Receptor and SRY/SOX Interaction in Prostate
前列腺中雄激素受体和 SRY/SOX 相互作用
  • 批准号:
    7240544
  • 财政年份:
    2003
  • 资助金额:
    $ 12.9万
  • 项目类别:
Androgen Receptor and SRY/SOX Interaction in Prostate
前列腺中雄激素受体和 SRY/SOX 相互作用
  • 批准号:
    7082037
  • 财政年份:
    2003
  • 资助金额:
    $ 12.9万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.9万
  • 项目类别:
    Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
  • 批准号:
    10828252
  • 财政年份:
    2023
  • 资助金额:
    $ 12.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了